Leucci, Eleonora

p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC

Christoffersen, N. R., Shalgi, R., Frankel, L. B., Leucci, E., Lees, M., Klausen, M., Pilpel, Y., Nielsen, F. C., Oren, M., & Lund, A. H. (2010) · Cell Death & Differentiation

Telomeres, Telomerase, and SenescenceMicroRNA in disease regulation

Cited by 352

Codon-specific translation reprogramming promotes resistance to targeted therapy

Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., et al. (2018) · Nature

RNA modifications and cancerRNA and protein synthesis mechanisms

Cited by 271

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities

Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer

Cancer Cells and MetastasisMathematical Biology Tumor Growth

Cited by 210

A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma

Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., et al. (2024) · Cell

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 199

Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo

Leucci, E., Zriwil, A., Gregersen, L. H., Jensen, K. T., Obad, S., Bellan, C., Leoncini, L., Kauppinen, S., & Lund, A. H. (2012) · Oncogene

MicroRNA in disease regulationCancer-related molecular mechanisms research

Cited by 89

The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma

Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022) · EMBO Molecular Medicine

Melanoma and MAPK PathwaysChromatin Remodeling and Cancer

Cited by 26